Regor Therapeutics has raised $90 million in a Series B financing round towards the discovery and development of discovery of drugs for cancer, immune disorders, and metabolic diseases by leveraging its Computer Accelerated Rational Discovery platform (CARD platform).

Lilly Asia Ventures led the Series B round of the clinical stage biotechnology company, which was established in July 2018.

Other participants of the funding round were Loyal Valley Capital, TF Capital, Lanting Capital, and Vertex Ventures China.

Dr. Yi Shi – managing partner of Lilly Asia Ventures said: “We are proud to support Regor Therapeutics’ world-class team to expand its efforts across a larger number of programs and therapeutic areas to develop tomorrow’s life-saving treatments.”

Regor Therapeutics was established following a Series A investment from Chinese pharma company Qilu Pharmaceutical Group.

By leveraging the CARD platform, the team of Regor Therapeutics is said to have advanced various discovery programs in a relatively short time.

Dr. Xiayang Qiu – Founder and CEO of Regor Therapeutics said: “We are very pleased with the strong support from leading life science investment firms in this financing round. We are now in a strong position to advance pre-clinical and clinical studies of multiple programs.

“We are looking forward to long-term collaborations with our investors, as we aim to improve the treatment outcomes for worldwide patients of chronic diseases, cancer and other life-threatening diseases.”

  China, Dr. Xiayang Qiu, Dr. Yi Shi, Lanting Capital, Lilly Asia Ventures, Loyal Valley Capital, Qilu Pharmaceutical Group, Regor Therapeutics, TF Capital, Vertex Ventures China